The European Medicines Agency (EMA) has granted a Marketing Authorisation Application (MAA) for a combination treatment targeting adults with acute myeloid leukaemia (AML) who are not candidates for standard induction chemotherapy. The MMA was granted to Otsuka Pharmaceutical and Astex Pharmaceuticals’ oral fixed-dose combination of decitabine and cedazuridine (ASTX727). The current standard of care for […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!
